about
Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemiaMutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cellsIncreased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells.Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia.Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.Intraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia.Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia.Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia.Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia CellsB cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia.Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression.Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcomeA seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes.Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells.PNAEmu can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease.The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways.Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma.Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.Production of inflammatory cytokines by Epstein-Barr virus (EBV)-infected lymphoblastoid cell lines spontaneously originated from the peripheral blood of patients with human immunodeficiency virus (HIV) infection.H and L ferritin gene expression in U937 cells induced to macrophage differentiation.Transforming growth factor beta-1 (TGF-beta 1) released by an Epstein-Barr virus (EBV) positive spontaneous lymphoblastoid cell line from a patient with Kostmann's congenital neutropenia inhibits the growth of normal committed haemopoietic progenitoValidation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.Expression of immunoglobulin receptors with distinctive features indicating antigen selection by marginal zone B cells from human spleen.Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway.The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.Toll-like receptor 9 stimulation can induce IκBζ expression and IgM secretion in chronic lymphocytic leukemia cells.High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells.B lymphocytes in humans express ZAP-70 when activated in vivo.Igs expressed by chronic lymphocytic leukemia B cells show limited binding-site structure variability.Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia.
P50
Q28208040-54D55A28-2CD6-4468-88C5-68D4CA842B12Q29048163-01AE3BDF-1078-48D8-BE14-A5CFDD720F3CQ33379988-6D9090E1-4C71-4B6D-A3AE-DA17ED1E0EDDQ34481433-5F66B429-0B88-47F7-B67E-96CDD9F3C546Q34978154-6BB97A13-37E7-44F6-A4ED-7F55BFF5306DQ35100546-015EF9A4-AEB8-4CED-A860-F025B875CE51Q35136742-5E541D9B-D45F-47F4-83B6-4DCD25CEE9CCQ35140580-3BE4E91D-12AD-4DE8-B1ED-161B3D1F5412Q35192691-6DC468D2-B750-43FA-A5C9-5C8B9C92B3E5Q35754594-8CE1B381-603D-4F69-B227-A0A0612A2D13Q35954301-8C28DC6A-61DC-4F47-BF9F-5A56E98308AFQ36779686-08BDEE9A-1DD5-4CCA-A90D-BF1D1BBE0DFCQ37179155-B825C0DD-7E3C-4D61-8BAD-DA18FB72F7A0Q37351173-A80EA77A-7B85-4016-970A-54FCCB25555CQ37634745-5E762D46-BC42-4813-99BF-B0CBF41A2912Q38410532-9B63DB2E-FA03-4198-9E12-C2C4FDECC399Q38822886-11EEF90A-ACAC-41F2-B29E-7EE831E1C5D1Q38839768-E18D5C1C-16A7-441E-85AC-D9F5DC119C59Q38945628-7C58E2BC-2579-4A8C-A04A-4EF1C82742E6Q39039713-F2A4EE7C-42E6-4504-AE7E-6AB713D30DE7Q39733717-E11C03EE-951C-4402-8A0D-02C234599813Q39861481-13F7E0B2-2121-4C1A-AD81-8C7B6D8F373AQ40067429-72290E5F-2F3E-4029-88D3-46D77D9C61ABQ40403348-CC04EA26-D833-49DC-B27F-678DE2C42501Q41092333-AEE3D9D6-CEE1-42E3-B587-825897B7D7E1Q41278222-1326108A-37E5-444F-98EF-9324F27610D8Q41511994-EC98B204-745C-4326-BF0C-FFC32D17572EQ41512659-8506CED4-DFA1-41B9-8C6E-1E1980A4B654Q42336286-A2280DC4-AE0E-49A6-A33F-6521E951C157Q42610409-612DC156-2946-4124-A8A5-31623039D890Q42620930-7D1AB6CB-3936-43AF-BC0B-204A55518CD3Q42711562-B4FA9361-EE7D-4B82-9811-ACFC58B50614Q44447816-D457EDB4-F40F-4069-AED3-93D010D88768Q45181930-DC08FAF8-D538-4118-B93F-86AFDE5D0AFCQ45938784-725E0DC2-D955-49A3-9B99-18C0039029ABQ46444068-21031B2D-4A4B-47F0-ADD2-B186402538C0Q46744099-D10EDA39-769F-4BB8-AA2C-ABB596150BD5Q46947867-C9BF34C9-923D-416D-A13F-340D8402DED8Q47574040-B8CA275C-D9E6-40C5-98F9-3436DBCDC34AQ47751529-8014A011-9A1F-4214-8143-5C7640EFE0DC
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giovanna Cutrona
@ast
Giovanna Cutrona
@en
Giovanna Cutrona
@es
Giovanna Cutrona
@nl
Giovanna Cutrona
@sl
type
label
Giovanna Cutrona
@ast
Giovanna Cutrona
@en
Giovanna Cutrona
@es
Giovanna Cutrona
@nl
Giovanna Cutrona
@sl
prefLabel
Giovanna Cutrona
@ast
Giovanna Cutrona
@en
Giovanna Cutrona
@es
Giovanna Cutrona
@nl
Giovanna Cutrona
@sl
P108
P106
P1153
7004025425
P21
P31
P496
0000-0002-3335-1101